Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 20, Number 4—April 2014
Research

Ciprofloxacin Resistance and Gonorrhea Incidence Rates in 17 Cities, United States, 1991–2006

Harrell W. ChessonComments to Author , Robert D. Kirkcaldy, Thomas L. Gift, Kwame Owusu-Edusei, and Hillard S. Weinstock
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Figure

Ciprofloxacin resistance and gonorrhea incidence rates in 17 cities, United States, 1991–2006. A) Gonorrhea incidence rates and B) average percentage of isolates resistant to ciprofloxacin for 2 groups of cities with higher (above the median) and lower (at or below the median) percentages of isolates resistant to ciprofloxacin as of 2004. Cities with higher resistance were Denver (Colorado), Honolulu (Hawaii), Minneapolis (Minnesota), Phoenix (Arizona), Portland (Oregon), San Diego (California),

Figure. . . Ciprofloxacin resistance and gonorrhea incidence rates in 17 cities, United States, 1991–2006. A) Gonorrhea incidence rates and B) average percentage of isolates resistant to ciprofloxacin for 2 groups of cities with higher (above the median) and lower (at or below the median) percentages of isolates resistant to ciprofloxacin as of 2004. Cities with higher resistance were Denver (Colorado), Honolulu (Hawaii), Minneapolis (Minnesota), Phoenix (Arizona), Portland (Oregon), San Diego (California), San Francisco (California), and Seattle (Washington). Cities with lower resistance were Albuquerque (New Mexico), Atlanta (Georgia), Baltimore (Maryland), Birmingham (Alabama), Cincinnati (Ohio), Cleveland (Ohio), New Orleans (Louisiana), Philadelphia (Pennsylvania), and St. Louis (Missouri).

Main Article

Page created: March 12, 2014
Page updated: March 12, 2014
Page reviewed: March 12, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external